A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

Green Cross Corporation

Status and phase: Completed; Phase 2

Conditions: Hepatitis B Infection

Treatments: Biological: GC1102 80,000 IU; Biological: GC1102 50,000 IU

Study type: Interventional

Funder types: Industry

Identifiers

NCT02304315

GC1102_P2

Details and patient eligibility

About

This is a proof-of-concept study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.

Full description

GC1102 is a new recombinant hepatitis B immunoglobulin (HBIg) from Chinese Hamster Ovary (CHO) cells. It is a monoclonal antibody and has high affinity and avidity to hepatitis B surface antigen and several advantages compared to HBIg derived from blood plasma of human donors. Forty volunteers will participate in the study, receive 24-week treatment with low dose (50,000IU) of GC1102 or with high dose (80,000IU) and be followed up till 28 weeks.

Enrollment: 40 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Given written informed consent
• Aged 19 - 65 years
• Expected liver transplantation related to hepatitis B
• Positive HBsAg

Exclusion criteria

• Patients has participated in any other clinical trial within 30 days
• Patients who are scheduled re-operation for liver transplantation
• Patients with are co-infected with HAV, HCV or HIV
• History of malignant tumor within 5 years except primary liver cancer
• Patients with moderate or severe renal disorder (serum creatinine > 1.5 X ULM) or anuria, acute renal failure or dialysis
• Patients who had experienced cardiovascular attack, myocardiac infarction, PTCA or coronary bypass or with angina, arrhythmia, or any other clinically meaningful valvular heart disease, cerebral infarction or cerebral hemorrhage within 6 months
• History of anaphylaxis against active ingredient or excipients of study drug
• Patients who had been vaccinated with parenteral live vaccine (measles vaccine, epidemic parotitis vaccine, rubella vaccine, cholera vaccine, chickenpox vaccine) within 3 months
• Patients who had been treated with any other immuno globulin within 3 months
• Pregnant or breast-feeding women
• Women of childbearing potential who do not agree to use appropriate contraceptive methods (condom, an intrauterine device, oral contraceptive hormones, or a vasectomy of male sex partner) during this study
• Alcohol or drug abuse within 6 months
• Patients who has any clinically meaningful disease in investigator's judgement to prevent participating in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

GC1102 50,000 IU

Experimental group

Description:

Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.

Treatment:

Biological: GC1102 50,000 IU

GC1102 80,000 IU

Experimental group

Description:

Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.

Treatment:

Biological: GC1102 80,000 IU